Alentis Therapeutics

Alentis Therapeutics company information, Employees & Contact Information

Alentis Therapeutics is a clinical-stage biotechnology company pioneering first-in-class antibody-drug conjugates (ADCs) and antibodies targeting Claudin-1 (CLDN1) for oncology and multi-organ fibrosis. CLDN1 is a previously unexploited target that plays a key role in the pathology of cancer and fibrotic disease. Alentis is the leading company pioneering CLDN1 ADCs and antibodies to modify and reverse the course of select diseases. Alentis was founded based on ground-breaking research in the laboratory of Prof. Thomas Baumert, MD at the University of Strasbourg and the French National Institute of Health and Medical Research (Inserm). Alentis is headquartered at the pharma-biotech hub in Basel, Switzerland. Visit www.alentis.ch

Company Details

Employees
65
Founded
-
Address
Hegenheimermattweg 167a, Allschwil,basel-Country 4123,switzerland
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Allschwil, Basel-Country
Looking for a particular Alentis Therapeutics employee's phone or email?

Alentis Therapeutics Questions

News

Alentis Appoints Mark Pruzanski as CEO - Business Wire

Alentis Appoints Mark Pruzanski as CEO Business Wire

Alentis Therapeutics Raises $181.4 Million in an Oversubscribed Series D Financing to Advance the Clinical Development of Anti-Claudin-1 ADCs in Solid Tumors - Yahoo Finance

Alentis Therapeutics Raises $181.4 Million in an Oversubscribed Series D Financing to Advance the Clinical Development of Anti-Claudin-1 ADCs in Solid Tumors Yahoo Finance

Alentis Announces Positive Topline Results from Two Studies of Lixudebart (ALE.F02) in Patients with ANCA-RPGN and Advanced Liver Fibrosis - BioSpace

Alentis Announces Positive Topline Results from Two Studies of Lixudebart (ALE.F02) in Patients with ANCA-RPGN and Advanced Liver Fibrosis BioSpace

FDA Grants Fast Track Designation to ALE.P02 for CLDN1+ Squamous Solid Tumors - OncLive

FDA Grants Fast Track Designation to ALE.P02 for CLDN1+ Squamous Solid Tumors OncLive

Alentis Therapeutics Gains $181.4 Million Funding to Advance Anti-Claudin-1 ADCs in Solid Tumors - BioPharm International

Alentis Therapeutics Gains $181.4 Million Funding to Advance Anti-Claudin-1 ADCs in Solid Tumors BioPharm International

Alentis Therapeutics raises USD 181.4M to develop new cancer and fibrosis treatments - Venturelab Swiss

Alentis Therapeutics raises USD 181.4M to develop new cancer and fibrosis treatments Venturelab Swiss

Antibody Drug Conjugate Targeting CLDN1 Receives FDA Fast Track Designation - Pharmacy Times

Antibody Drug Conjugate Targeting CLDN1 Receives FDA Fast Track Designation Pharmacy Times

Novo Holdings, OrbiMed, Jeito lead $181M fundraise for ADC biotech - Fierce Biotech

Novo Holdings, OrbiMed, Jeito lead $181M fundraise for ADC biotech Fierce Biotech

ALE.P02 Gains FDA Fast Track Status in CLDN1+ Solid Tumors - Targeted Oncology

ALE.P02 Gains FDA Fast Track Status in CLDN1+ Solid Tumors Targeted Oncology

Alentis doubles down on Claudin1 | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Alentis doubles down on Claudin1 | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Alentis Therapeutics reports positive results from organ fibrosis treatment trials - Clinical Trials Arena

Alentis Therapeutics reports positive results from organ fibrosis treatment trials Clinical Trials Arena

Christos Hatzis: I have joined Alentis Therapeutics as the Head of Translational Medicine - Oncodaily

Christos Hatzis: I have joined Alentis Therapeutics as the Head of Translational Medicine Oncodaily

Alentis to move Claudin-targeting ADCs into the clinic with fresh $181M - FirstWord Pharma

Alentis to move Claudin-targeting ADCs into the clinic with fresh $181M FirstWord Pharma

Alentis Therapeutics Expands Leadership Team with the Appointment of Rizwan Velji as Chief Business Officer - BioSpace

Alentis Therapeutics Expands Leadership Team with the Appointment of Rizwan Velji as Chief Business Officer BioSpace

Alentis Appoints Jonathan Freve CFO - Business Wire

Alentis Appoints Jonathan Freve CFO Business Wire

Alentis Appoints Alberto Toso Chief Scientific Officer - Business Wire

Alentis Appoints Alberto Toso Chief Scientific Officer Business Wire

William Pao Joins Alentis Therapeutics as Independent Board Member - Business Wire

William Pao Joins Alentis Therapeutics as Independent Board Member Business Wire

Alentis doses first subject in organ fibrosis therapy trial - Clinical Trials Arena

Alentis doses first subject in organ fibrosis therapy trial Clinical Trials Arena

Pruzanski named CEO of Alentis - BioCentury

Pruzanski named CEO of Alentis BioCentury

Alentis nabs $181M to broaden Claudin’s scope in ADCs - Endpoints News

Alentis nabs $181M to broaden Claudin’s scope in ADCs Endpoints News

FDA Grants Fast Track Status to ALE.C04 for Recurrent or Metastatic CLDN1+ HNSCC - OncLive

FDA Grants Fast Track Status to ALE.C04 for Recurrent or Metastatic CLDN1+ HNSCC OncLive

Alentis Therapeutics Appoints Dr. Andrea Pellacani as Chief Medical Officer - Business Wire

Alentis Therapeutics Appoints Dr. Andrea Pellacani as Chief Medical Officer Business Wire

Mark Pruzanski joins Alentis as CEO after leading Intercept and Versanis - Endpoints News

Mark Pruzanski joins Alentis as CEO after leading Intercept and Versanis Endpoints News

Alentis doses first subject in Phase I/II HNSCC antibody trial - Clinical Trials Arena

Alentis doses first subject in Phase I/II HNSCC antibody trial Clinical Trials Arena

Don’t Call It a Crossover, but Alentis Raises $181M Series D for ADC Work - BioSpace

Don’t Call It a Crossover, but Alentis Raises $181M Series D for ADC Work BioSpace

Alentis reports positive results from fibrosis study - Labiotech.eu

Alentis reports positive results from fibrosis study Labiotech.eu

Alentis rides in zolbetuximab's slipstream to secure $105M series C for anti-fibrotic ambitions - Fierce Biotech

Alentis rides in zolbetuximab's slipstream to secure $105M series C for anti-fibrotic ambitions Fierce Biotech

Alentis Therapeutics Receives FDA IND Clearance for ALE.P02, a Novel CLDN1-ADC for the Treatment of Squamous Cancers - BioSpace

Alentis Therapeutics Receives FDA IND Clearance for ALE.P02, a Novel CLDN1-ADC for the Treatment of Squamous Cancers BioSpace

Alentis Therapeutics’ anti-CLDN1 ADC gains IND clearance - BioWorld MedTech

Alentis Therapeutics’ anti-CLDN1 ADC gains IND clearance BioWorld MedTech

Novo Holdings co-leads $181.4 million financing in Alentis - The Pharma Letter

Novo Holdings co-leads $181.4 million financing in Alentis The Pharma Letter

Alentis Names Dr. Alberto Toso as Chief Scientific Officer - Contract Pharma

Alentis Names Dr. Alberto Toso as Chief Scientific Officer Contract Pharma

Swiss Biotech Raises €11M to Develop Treatments for Liver Fibrosis - Labiotech.eu

Swiss Biotech Raises €11M to Develop Treatments for Liver Fibrosis Labiotech.eu

Claudin-1-targeted therapies break barriers in precision oncology - Nature

Claudin-1-targeted therapies break barriers in precision oncology Nature

Alentis Therapeutics - The Pharma Letter

Alentis Therapeutics The Pharma Letter

Switzerland: Alentis appoints Mark Pruzanski as CEO - Investors in Healthcare

Switzerland: Alentis appoints Mark Pruzanski as CEO Investors in Healthcare

Alentis’ ALE.C04 receives fast track designation from FDA - Pharmaceutical Business review -

Alentis’ ALE.C04 receives fast track designation from FDA Pharmaceutical Business review -

Alentis Therapeutics Names Roberto Iacone CEO - BioSpace

Alentis Therapeutics Names Roberto Iacone CEO BioSpace

Top Alentis Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant